Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals (Nasdaq: IONS) announced participation in virtual fireside chats at two major investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals (Nasdaq: IONS) announced participation in virtual fireside chats at two major investor conferences. The Bank of America Healthcare Conference is scheduled for May 12, 2021, and the RBC Capital Markets Global Healthcare Conference on May 19, 2021. The company will provide updates on presentation times and changes via its website. Live webcasts will be accessible in the Investors & Media section, with replays available within 48 hours. Ionis is recognized for its leadership in RNA-targeted therapy and has three marketed medicines.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was -6.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., May 6, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following investor conferences:
- Bank of America Healthcare Conference on Wednesday, May 12, 2021
- RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.ionispharma.com for the latest information.
A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-301285004.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.